Loading...

Lansen Pharmaceutical Holdings Limited

0503.HK•HKSE
Healthcare
Drug Manufacturers - Specialty & Generic
HK$1.79
HK$0.52(40.94%)
empty-state-iconFinancials data is not available for this stockFinancials details for this stock are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Over the last four quarters, Lansen Pharmaceutical Holdings Limited's revenue moved from $16.78M in Q3 2022 to $15.69M in Q2 2023. Operating income in Q2 2023 was $3.77M, with a strong operating margin of 24%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Lansen Pharmaceutical Holdings Limited remained robust at $4.30M, reflecting operational efficiency. Net income rose to $2.81M, with an EPS of $0.007. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;